Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2001037815) OSMOTIC DOSAGE FORM COMPRISING FIRST AND SECOND
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2001/037815 International Application No.: PCT/US2000/032065
Publication Date: 31.05.2001 International Filing Date: 21.11.2000
Chapter 2 Demand Filed: 11.06.2001
IPC:
A61K 9/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
Applicants:
ALZA CORPORATION [US/US]; 1900 Charleston Road P.O. Box 7210 Mountain View, CA 94039-7210, US
Inventors:
AYER, Atul, D.; US
SHIVANAND, Padmaja; US
Agent:
DHUEY, John, A. ; Alza Corporation 1900 Charleston Road (P.O. Box 7210) Mountain View, CA 94039-7210, US
NELLER, Robert, R.; Alza Corporation 1900 Charleston Road (P.O. Box 7210) Mountain View, CA 94039-7210, US
Priority Data:
60/166,78022.11.1999US
Title (EN) OSMOTIC DOSAGE FORM COMPRISING FIRST AND SECOND
(FR) FORME POSOLOGIQUE OSMOTIQUE COMPRENANT UN PREMIER ET UN SECOND ENROBAGES
Abstract:
(EN) A dosage form is described having a drug core, an inner, fluid-permeable membrane surrounding the drug core, and an outer, semipermeable membrane having exit means formed or formable therein surrounding the inner membrane. The drug core forms a solution with imbibed fluid through the membranes and dissolves the inner membrane over time, thereby furthering the maintenance of controlled, sustained delivery of drug from the dosage form.
(FR) Cette invention concerne une forme posologique comprenant un noyau de médicament, une membrane intérieure perméable aux liquides et une membrane extérieure semi-perméable comportant un dispositif de sortie formé ou pouvant être formé sur ladite membrane, autour de la membrane intérieure. Le noyau de médicament forme une solution avec un liquide imprégnant les membranes et dissout à la longue la membrane intérieure, ce qui favorise l'administration régulée et soutenue du médicament à partir de la forme posologique.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)